Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Hans-Peter Vornlocher"'
Autor:
Anja Geisler, Babette Dieringer, Leslie Elsner, Karin Klingel, Robert Klopfleisch, Hans-Peter Vornlocher, Jens Kurreck, Henry Fechner
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 32, Iss , Pp 923-936 (2023)
RNA interference has demonstrated its potential as an antiviral therapy for treatment of human adenovirus (hAd) infections. The only existing viral vector-based system for delivery of anti-adenoviral artificial microRNAs available for in vivo use, ho
Externí odkaz:
https://doaj.org/article/8f857671448d4f67b3c18507d9e19145
Autor:
Ingmar Sören Meyer, Carl Christoph Goetzke, Meike Kespohl, Martina Sauter, Arnd Heuser, Volker Eckstein, Hans-Peter Vornlocher, Daniel G. Anderson, Jan Haas, Benjamin Meder, Hugo Albert Katus, Karin Klingel, Antje Beling, Florian Leuschner
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Myocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-in
Externí odkaz:
https://doaj.org/article/48b682ae3bcc48c7b00ba3d1e47c0c08
Autor:
Christian Dohmen, Thomas Fröhlich, Ulrich Lächelt, Ingo Röhl, Hans-Peter Vornlocher, Philipp Hadwiger, Ernst Wagner
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
Gene silencing mediated by small interfering RNA (siRNA) is a novel approach in the development of new cancer therapeutics. Polycations used for nucleic acid delivery still remain heterogeneous compounds, despite continuous progress in polymer synthe
Externí odkaz:
https://doaj.org/article/ffcf21b231c1400b93066867632fa998
Autor:
Hans-Peter Vornlocher, Brown Jonathan Miles, Monika Krampert, James E. Dahlman, Kristin K.H. Neuman, Carla Alexandra Hernandez Prata, Philipp Hadwiger
Publikováno v:
Nucleic Acid Therapeutics
Small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) ligands have been used to treat disease in patients. However, conjugates with other ligands deliver siRNA less efficiently, limiting the development of new targeted therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948585e8df8e17f94b3659e972d8eb5e
https://doi.org/10.1089/nat.2019.0782
https://doi.org/10.1089/nat.2019.0782
Autor:
Florian Kuchenbauer, Martin Stangel, Amit Sharma, Michael Heuser, Michaela Scherr, Pieter R. Cullis, Korbinian Brand, Matthias Eder, Fatih Noyan, Nidhi Jyotsana, R. Keith Humphries, Hans-Peter Vornlocher, Kurt-Wolfram Sühs, Anuhar Chaturvedi, Euan Ramsay, Felicitas Thol, Arnold Ganser, Ramachandramouli Budida, Robert Lindner, Denis Grote-Koska
Publikováno v:
Ann Hematol
Annals of Hematology
Annals of Hematology
Efficient and safe delivery of siRNA in vivo is the biggest roadblock to clinical translation of RNA interference (RNAi)-based therapeutics. To date, lipid nanoparticles (LNPs) have shown efficient delivery of siRNA to the liver; however, delivery to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5bf59b7f84b04f202302ac5bbf2eb7e
https://doi.org/10.1007/s00277-019-03713-y
https://doi.org/10.1007/s00277-019-03713-y
Autor:
Euan Ramsay, Arnold Kloos, Felicitas Thol, Anitha Thomas, Florian Grebien, Nidhi Jyotsana, Amit Sharma, Hans-Peter Vornlocher, Sagarajit Mohanty, Johannes Schmoellerl, Michael Heuser, Madhvi Mandhania, Basem Othman, Courteney K. Lai, Arnold Ganser, Razif Gabdoulline, Renate Schottmann
Publikováno v:
Cancers
Volume 12
Issue 10
Cancers, Vol 12, Iss 2766, p 2766 (2020)
Volume 12
Issue 10
Cancers, Vol 12, Iss 2766, p 2766 (2020)
Simple Summary NUP98-NSD1-positive acute myeloid leukemia (AML) frequently shows an additional mutation in Neuroblastoma rat sarcoma (NRAS). However, the synergistic effect of NUP98-NSD1 and NRASG12D in leukemic transformation remained unclear. In ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cadde40fbee4fd56cc63afc0a130e9c2
https://doi.org/10.3390/cancers12102766
https://doi.org/10.3390/cancers12102766
Autor:
Arnold Ganser, Hans Peter Vornlocher, Amit Sharma, Basem Othman, Sagarajit Mohanty, Euan Ramsay, Felicitas Thol, Nidhi Jyotsana, Michael Heuser, Renate Schottmann, Arnold Kloos, Madhvi Mandhania
Publikováno v:
Blood. 134:2545-2545
Background: NUP98-NSD1 positive AML is a poor prognostic subgroup within pediatric and adult AML (Thol et al., 2013). However, targeted therapeutics for these AML patients are not available to date. As a result of the NUP98-NSD1 fusion, NSD1 causes H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00b977b1ee8b35d0411c276f779b0d0d
https://doi.org/10.1182/blood-2019-123709
https://doi.org/10.1182/blood-2019-123709
Autor:
Darren H. Wakefield, Kerstin Jahn-Hofmann, Julia Hegge, Claudia E. Oropeza, Hans-Peter Vornlocher, Markus Hossbach, Qili Chu, David B. Rozema, Ingo Roehl, Alan McLachlan, Holly Hamilton, Philipp Hadwiger, Christine I. Wooddell, Matthias John, Jason Klein, Jochen Deckert, David L. Lewis
Publikováno v:
Molecular Therapy
RNA interference (RNAi)-based therapeutics have the potential to treat chronic hepatitis B virus (HBV) infection in a fundamentally different manner than current therapies. Using RNAi, it is possible to knock down expression of viral RNAs including t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd54760eecf60d79cd46602fcf7f0c3a
Autor:
Donald Riley, Joanne Kamens, Saraswathy Nochur, Laurence O. Whiteley, Scott P. Henry, Steven R. Bartz, Husam S. Younis, Morten Lindow, Arthur A. Levin, Hans-Peter Vornlocher, Joel D. Parry, James D. Thompson, Douglas J. Kornbrust, Julja Burchard, Nicolay Ferrari
Publikováno v:
Nature Biotechnology. 30:920-923
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009a9d7e926ac5dbf5afe84e7c5fe0b3
https://doi.org/10.1038/nbt.2376
https://doi.org/10.1038/nbt.2376
Autor:
Philipp Hadwiger, Daniel Edinger, Joachim O. Rädler, Hans-Peter Vornlocher, Ulrich Lächelt, Thomas Fröhlich, Christina Troiber, Laura Schreiner, Ernst Wagner, Christian Dohmen
Publikováno v:
ACS Nano. 6:5198-5208
Although our understanding of RNAi and our knowledge on designing and synthesizing active and safe siRNAs significantly increased during the past decade, targeted delivery remains the major limitation in the development of siRNA therapeutics. On one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d68435eef36a8625495be76f4d82f37c
https://doi.org/10.1021/nn300960m
https://doi.org/10.1021/nn300960m